NYSE - Nasdaq Real Time Price USD

Eli Lilly and Company (LLY)

Compare
888.64 +10.19 (+1.16%)
As of 2:35 PM EDT. Market Open.
Loading Chart for LLY
DELL
  • Previous Close 878.45
  • Open 878.00
  • Bid 887.64 x 2200
  • Ask 888.15 x 900
  • Day's Range 876.86 - 892.20
  • 52 Week Range 434.34 - 892.20
  • Volume 1,379,568
  • Avg. Volume 2,590,179
  • Market Cap (intraday) 844.568B
  • Beta (5Y Monthly) 0.36
  • PE Ratio (TTM) 131.46
  • EPS (TTM) 6.76
  • Earnings Date Aug 8, 2024
  • Forward Dividend & Yield 5.20 (0.59%)
  • Ex-Dividend Date May 15, 2024
  • 1y Target Est 863.79

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

www.lilly.com

43,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: LLY

Performance Overview: LLY

Trailing total returns as of 6/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

LLY
52.97%
S&P 500
14.99%

1-Year Return

LLY
99.97%
S&P 500
24.39%

3-Year Return

LLY
316.17%
S&P 500
29.86%

5-Year Return

LLY
755.56%
S&P 500
89.99%

Compare To: LLY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LLY

Valuation Measures

Annual
As of 6/14/2024
  • Market Cap

    834.88B

  • Enterprise Value

    858.51B

  • Trailing P/E

    129.37

  • Forward P/E

    64.10

  • PEG Ratio (5yr expected)

    2.60

  • Price/Sales (ttm)

    22.09

  • Price/Book (mrq)

    65.16

  • Enterprise Value/Revenue

    23.89

  • Enterprise Value/EBITDA

    88.60

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    17.08%

  • Return on Assets (ttm)

    12.60%

  • Return on Equity (ttm)

    50.75%

  • Revenue (ttm)

    35.93B

  • Net Income Avi to Common (ttm)

    6.14B

  • Diluted EPS (ttm)

    6.76

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2.65B

  • Total Debt/Equity (mrq)

    204.28%

  • Levered Free Cash Flow (ttm)

    -1.23B

Research Analysis: LLY

Company Insights: LLY

Research Reports: LLY

People Also Watch